00000750613

Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
B-106 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510

RECEIVED.
SECRETARY OF THE SENATE
04 AUG 13 AM 10: 13

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required to Complete This Page**

1. Registrant Name
Bristol-Myers Squibb Company

2. Registrant Address ☐ Check if different than previously reported
Address **655 15th St., NW**
City **Washington, DC** State/Zip (or Country) **20005** **USA**

3. Principal Place of Business (if different from line 2)
City State/Zip (or Country)

4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Richard Thompson	**202-783-8618**		**7053-12**

7. Client Name ☒ Self	6. House ID #
	7053

TYPE OF REPORT

8. Year **2004** Midyear (January 1-June 30) ☒ **OR** Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____ 11. No Lobby

INCOME OR EXPENSES - Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than $10,000 ☐

$10,000 or more ☐ >> $ _____
Income (nearest $20,000)

Provide a good faith estimate, rounded to the nearest $20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this rep period were:

Less than $10,000 ☐

$10,000 or more ☒ >> $ **$2,720,000.00**
Expenses (nearest $20

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of

☒ **Method A.** Reporting amounts using LDA definit

☐ **Method B.** Reporting amounts under section 603 the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(Internal Revenue Code

8/13/2004

Signature _____ Date 6/12/2009

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **ADV** (one per page)

16. Specific Lobbying issues
H.R.149 , Say No to Drug Ads Act, Lobbied to ensure that any restrictions did not inadvertently impede the access to accurate information about pharmaceutical products.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **BUD** (one per page)

16. Specific Lobbying issues
H.R., Department of Labor, Health and Human Serivces, and Education, and Related Agencies Approrpria 2005, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
H.R.4766, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Approrp 2005, Lobbied to ensure safety of prescription drugs and adequate funding for FDA.
S., Department of Labor, Health and Human Serivces, and Education, and Related Agencies Approrpriatio Lobbied to prevent the passage of provisions and amendments that are adverse to the industry and encoura study on cancer delivery services.
S.1, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Approrpriatio Lobbied to prevent the passage of provisions and amendments that are adverse to the industry and encoura study on cancer delivery services.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Keaney, David	
Ryan, John	
Thompson, Richard	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **CAW** (one per page)

16. Specific Lobbying issues
S.6 , Wastewater Treatment Works Security and Safety Act. A bill to enhance homeland security and for otl
Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **CPT** (one per page)

16. Specific Lobbying issues
H.R.1561 , United States Patent and Trademark Fee Modernization Act of 2003, Lobbied to prevent amendı would undermine industry intellectual property and other interests.
H.R.2344 , Intellectual Property Protection Restoration Act of 2003, Lobbied to prevent amendments that w undermine industry intellectual property and other interests.
H.R.2391 , Cooperative Research and Technology Enhancement (CREATE) Act of 2003, Lobbied to prevent that would undermine industry intellectual property and other interests.
H.R.2461 , Equal Access to Prescription Drugs for All Seniors Act, Lobbied to prevent amendments that wo undermine industry intellectual property and other interests.
H.R.2491 , Greater Access to Affordable Pharmaceuticals Act, Lobbied to ensure that any Hatch/Waxman A are fair and balanced.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Keaney, David	
Ryan, John	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 6/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pag

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	H.R.2640 , To provide greater access to affordable pharmaceuticals, and for purposes., Lobbied to prevent the passage of amendments that are adverse to industry.
16	Lobbying Issues	H.R.2700 , Medicare Patient Access to Drugs for Rare Diseases Act of 2003, Lobbied to prevent amendments that would undermine industry intellectual property and other interests.
16	Lobbying Issues	H.R.2947 , Making Health Care Available for Low Income Workers Act of 2 Lobbied to ensure that any Hatch/Waxman Act reforms are fair and balance
16	Lobbying Issues	H.R.3401 , Generic Drugs Access Act of 2003, Lobbied to prevent amendmen that would undermine industry intellectual property and other interests.
16	Lobbying Issues	H.R.909 , To amend title 35, United States Code, to direct the Director of the Patent and Trademark Office to adjust fees charged by the Office so that the collected in any fiscal year will equal, to the greatest extent practicable, the amount appropriated to , Lobbied to prevent amendments that would under industry intellectual property and other interests.
16	Lobbying Issues	S.1191 , Intellectual Property Protection Restoration Act of 2003, Lobbied to prevent amendments that would undermine industry intellectual property an other interests.
16	Lobbying Issues	S.51 , Generic Pharmaceutical Access and Choice for Consumers Act of 2003 Lobbied to prevent the passage of provisions and amendments that are adver the industry.
16	Lobbying Issues	S.54 , Greater Access to Affordable Pharmaceuticals Act of 2003, Lobbied to ensure that any Hatch/Waxman Act reforms are fair and balanced.
16	Lobbying Issues	S.946 , Drug Competition Act of 2003, Lobbied to prevent amendments that undermine industry intellectual property and other interests.

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **CSP** (one per page)

16. Specific Lobbying issues
H.R.1197 , Product Safety Notification and Recall Effectiveness Act of 2003, Lobbied to prevent the passage and amendments that are adverse to the industry.
H.R.1636 , Consumer Privacy Protection Act of 2003, Lobbied to prevent the passage of provisions and ame are adverse to the industry.
H.R.1709 , Stop Taking Our Health Privacy (STOHP) Act of 2003, Lobbied to prevent the passage of provis amendments that are adverse to the industry.
H.R.1766 , National Uniform Privacy Standards Act of 2003, Lobbied to prevent the passage of provisions a amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new
H.R.1931 , Personal Information Privacy Act of 2003, Lobbied to prevent the passage of provisions and ame would restrict the industry's ability to utilize clinical trial data that is essential to find new cures.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	H.R.2196 , Medical Independence, Privacy, and Innovation Act of 2003, Lobl to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new cure:
16	Lobbying Issues	H.R.2544 , Medical Independence, Privacy, and Innovation Act of 2003, Lobl to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial data that is essential to find new cure:
16	Lobbying Issues	H.R.2652 , Internet Pharmacy Consumer Protection Act, Lobbied to prevent passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.663 , Patient Safety and Quality Improvement Act, Lobbied for legislati that would encourage and promote the sharing of information on quality pro and medical errors without the fear of costly and unnecessary litigation.
16	Lobbying Issues	H.R.781 , Privacy Protection Clarification Act, Lobbied to prevent the passa provisions and amendments that would restrict the industry's ability to utiliz clinical trial data that is essential to find new cures.
16	Lobbying Issues	S.1286 , Seniors Safety Act of 2003, Lobbied to prevent the passage of provisi and amendments that would restrict the industry's ability to utilize clinical tr data that is essential to find new cures.
16	Lobbying Issues	S.720 , Patient Safety and Quality Improvement Act, Lobbied for legislation would encourage and promote the sharing of information on quality problem medical errors without the fear of costly and unnecessary litigation.
16	Lobbying Issues	S.745 , Privacy Act of 2003, Lobbied to prevent the passage of provisions and amendments that would restrict the industry's ability to utilize clinical trial d that is essential to find new cures.

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **FOO** (one per page)

16. Specific Lobbying issues
H.R.1160 , Milk Import Tariff Equity Act, Lobbied to prevent restrictions on the importation of key ingredi infant formula.
S.154 , Emergency Agricultural Disaster Assistance Act of 2003, Lobbied to prevent restrictions on the impo ingredients for infant formula.
S.40 , Quality Cheese Act of 2003, Lobbied to prevent restrictions on the importation of key ingredients for i formula.
S.560 , Milk Import Tariff Equity Act, Lobbied to prevent restrictions on the importation of key ingredients formula.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date _____

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **FOR** (one per page)

16. Specific Lobbying issues
H.R.1298 , United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003, Lobbied to passage of provisions and amendments that are adverse to the industry.
H.R.1857 , Humanitarian Assistance to Combat HIV/AIDS in sub-Saharan Africa and the Caribbean and N Security Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the i
H.R.2069 , Stop Tuberculosis (TB) Now Act, Lobbied to prevent the passage of provisions and amendments adverse to the industry.
H.R.2470 , Medicines to Eliminate Diseases in Developing States Act, Lobbied to prevent the passage of pro amendments that are adverse to the industry.
S.1009 , United States Emergency Plan for AIDS Relief Act of 2003, Lobbied to prevent the passage of provi amendments that are adverse to the industry.
S.250 , Global CARE Act, Lobbied to prevent the passage of provisions and amendments that are adverse to

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
Department of Health & Human Services
House of Representatives
Office of U.S. Trade Representative
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	**Lobbying Issues**	**S.1067 , AIDS Corps Act of 2003, Lobbied to prevent the passage of provisio amendments that are adverse to the industry.**
16	**Lobbying Issues**	**S.859 , Microbicide Development Act of 2003, Lobbied to prevent the passag provisions and amendments that are adverse to the industry.**
16	**Lobbying Issues**	**Lobbied United States Trade Representitive on the efforts to weaken the intellectual property provisions of the U.S./Chile FTA on linkage and data protection, and reduce protections currently granted by the Chilean patent l such as second use patents.**

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **GOV** (one per page)

16. Specific Lobbying issues
H.R.1389 , Homeland Emergency Response Act of 2003, Lobbied to prevent the passage of provisions and a that are adverse to the industry.
H.R.1416 , Homeland Security Technical Corrections Act of 2003, Lobbied to prevent the passage of provisi amendments that are adverse to the industry.
S.15 , Biodefense Improvement and Treatment for America Act, Lobbied to prevent the passage of provisio amendments that are adverse to the industry.
S.1567 , Department of Homeland Security Financial Accountability Act, Lobbied to prevent the passage of and amendments that are adverse to the industry.
S.22 , Justice Enhancement and Domestic Security Act of 2003, Lobbied to prevent the passage of provision amendments that are adverse to the industry.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Keaney, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **HCR** (one per page)

16. Specific Lobbying issues
H.CON.RES.225 , Expressing the sense of the Congress that the illegal importation of prescription drugs sev undermines the regulatory protections afforded to United States consumers, and for other purposes, Lobbie the passage of provisions and amendments that are adverse to the industry.
H.R.1068 , Pancreatic Islet Cell Transplantation Act of 2003, Lobbied to prevent unnecessary restrictions or scientific and clinical research.
H.R.1120 , Health Care Antitrust Improvements Act of 2003, Lobbied to ensure and foster continued patien quality of care by clarifying the application of the antitrust laws to negotiations between groups of health ca professionals, health plans and health care insurance issuers.
H.R.1158 , Medical Liability Insurance Crisis Response Act of 2003, Lobbied to improve patient access to he services and products and to provide improved medical care by reducing the excessive burden the liability sy on the health care delivery system.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
Department of Health & Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Keaney, David	
Ryan, John	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Date **8/12/2004**

Signature _____ Date _____

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	H.R.1200 , American Health Security Act of 2003, Lobbied to prevent the pa of provisions that would impose unreasonable price controls on US manufact
16	Lobbying Issues	H.R.1205 , MediKids Health Insurance Act of 2003, Lobbied to ensure great access to pediatric pharmaceutical products for children and for the develop of better padiatric drugs.
16	Lobbying Issues	H.R.1243 , Prescription Drug Benefit Equity Act of 2003, Lobbied to prevent passage of provisions that would impose unreasonable price controls on US manufacturers.
16	Lobbying Issues	H.R.1247 , Quality Health Care Coalition Act of 2003, Lobbied to ensure and foster continued patient safety and quality of care by exempting health care professionals from the Federal antitrust laws in their negotiations with healtl plans and health insurance issuers.
16	Lobbying Issues	H.R.1309 , Veterans Prescription Drug Benefits Act of 2003, Lobbied to prev the passage of provisions that would impose unreasonable price controls on U manufacturers.
16	Lobbying Issues	H.R.15 , National Health Insurance Act, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to rec coverage for these products.
16	Lobbying Issues	H.R.1568 , Medicare Rx Now Act of 2003, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's seniors to rec coverage for these products.
16	Lobbying Issues	H.R.1622 , Quality Cancer Care Preservation Act, Lobbied to provide for gr access to affordable pharmcetuical products to treat cancer.
16	Lobbying Issues	H.R.1694 , Amerca Rx Act of 2003, Lobbied to prevent the passage of provis and amendments that would prevent the general public from being adequate informed about pharmacetuical products.
16	Lobbying Issues	H.R.2021 , Access to Cancer Clinical Trials Act of 2003, Lobbied to provide greater access to affordable pharmaceutical products to treat cancer.
16	Lobbying Issues	H.R.2068 , Comprehensive Tuberculosis Elimination Act of 2003, Lobbied to provide for greater access to affordable pharmaceutical products to treat Tuberculosis (TB).
16	Lobbying Issues	H.R.2069 , Stop Tuberculosis (TB) Now Act, Lobbied to provide for greater to affordable pharmaceutical products to treat Tuberculosis (TB).
16	Lobbying Issues	H.R.2122 , Project BioShield Act of 2003, Lobbied to ensure the reasonable efficient development of counter bioterrorism pharmaceutical products.
16	Lobbying Issues	H.R.2161 , Prescription Value Act, Lobbied to prevent the passage of provisi and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2196 , Medical Independence, Privacy, and Innovation Act of 2003, Lob to prevent the passage of provisions and amendments that would restrict the reasonable use of clinical data.
16	Lobbying Issues	H.R.2232 , To amend the Federal Food, Drug, and Cosmetic Act relating to t distribution chain of prescription drugs, Lobbied to prevent the passage of provisions and amendments that would increase the flow of imported harmfu counterfeit drug products into the USA.
16	Lobbying Issues	H.R.2258 , Hispanic Health Improvement Act of 2003, Lobbied to provide fo programs and activities to improve the health of Hispanic individuals.
16	Lobbying Issues	H.R.234 , Human Cloning Prohibition Act of 2003, Lobbied to prevent unne restrictions on legitimate scientific and clinical research.
16	Lobbying Issues	H.R.2356 , Prescription Drug Comparative Effectiveness Act of 2003, Lobbi prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2391 , Cooperative Research and Technology Enhancement (CREATE) 2003, Lobbied to prevent the passage of provisions and amendments that wo unneccessarily restrict the use of cooperative research and development agreements.

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	H.R.2402 , Health Coverage, Affordability, Responsibility, and Equity Act of Lobbied to prevent the passage of provisions and amendments that are adver the industry.
16	Lobbying Issues	H.R.2427 , Pharmaceutical Market Access Act of 2003, Lobbied to prevent th passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2461 , Equal Access to Prescription Drugs for All Seniors Act, Lobbied t prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2491, Greater Access to Affordable Pharmaceuticals Act, Lobbied to pr passage.
16	Lobbying Issues	H.R.2497 , Prescription Drug Parity for Americans Act, Lobbied to prevent passage of provisions that would impose unreasonable price controls on US manufacturers.
16	Lobbying Issues	H.R.2514 , Honor Thy Parents Act of 2003, Lobbied to prevent the passage o provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.2544 , Medical Independence, Privacy, and Innovation Act of 2003, Lob to prevent the passage of amendments and provisions that would restrict the reasonable use of clinical data.
16	Lobbying Issues	H.R.2577 , To require the Comptroller General to conduct a study and subm Congress a report on price controls of foreign governments on pharmaceutic Lobbied to require the Comptroller General to conduct a fair and balanced s on price controls of foreign governments on pharmaceuticals.
16	Lobbying Issues	H.R.2640 , To provide greater access to affordable pharmaceuticals, and for purposes, Lobbied to prevent the passage of provisions and amendments that adverse to the industry.
16	Lobbying Issues	H.R.2652 , Internet Pharmacy Consumer Protection Act, Lobbied to prevent passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.354 , North American Prescription Price Equity Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.3658, Stroke Treatment and Ongoing Prevention Act, Lobbied to ensure safety of prescription drugs and adequate funds for stroke programs.
16	Lobbying Issues	H.R.38 , More Savings, More Choice Prescription Drug Act of 2003, Lobbied provide a Medicare prescription drug benefit that will enable millions of Am seniors to receive coverage for these products.
16	Lobbying Issues	H.R.3873, Child Nutrition Improvement and Integrity Act, Lobbied to ensur passage of WIC program.
16	Lobbying Issues	H.R.5 , Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) 2003, Lobbied to improve patient access to health care services and products to provide improved medical care by reducing the excessive burden the liabli system places on the health care delivery system.
16	Lobbying Issues	H.R.534 , Human Cloning Prohibition Act of 2003, Lobbied to prevent the p of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	H.R.608 , Pharmaceutical Products Price Equity Act, Lobbied to prevent the passage of provisions that would import foreign price controls on US manufacturers.
16	Lobbying Issues	H.R.616 , Prescription Drug Affordability Act, Lobbied to prevent the passa provisions that would permit the importation of defective counterfeit foreign products or foreign price controls.
16	Lobbying Issues	H.R.634 , To provide Medicare beneficiaries with access to prescription dru Federal Supply Schedule prices, Lobbied to prevent the passage of provision amendments that are adverse to the industry.
16	Lobbying Issues	H.R.635 , To assure that enrollment in any Medicare prescription drug prog voluntary, Lobbied to provide a Medicare prescription drug beneift that will enable millions of America's seniors to receive coverage for these products.

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	H.R.676 , Expanded and Improved Medicare for All Act, Lobbied to provide Medicare prescription drug beneift that will enable millions of America's sen to receive coverage for these products.
16	Lobbying Issues	H.R.725 , Ephedrine Alkaloid Consumer Protection Act, Lobbied to provide Medicare prescription drug benefit that will enable millions of America's sen to receive coverage for these products.
16	Lobbying Issues	H.R.780 , Prescription Drug Price Reduction Act, Lobbied to prevent the pas of provisions that would impose unreasonable price controls on US manufact
16	Lobbying Issues	H.R.810 , Medicare Regulatory and Contracting Reform Act of 2003, Lobbie provide a Medicare prescription drug benefit that will enable millions of Am seniors to receive coverage for these products.
16	Lobbying Issues	H.R.828 , Pharmaceutical Fiscal Accountability Act of 2003, Lobbied to prev the passage of provisions that would impose unreasonable price controls on U manufacturers.
16	Lobbying Issues	H.R.847 , Preserving Access to Safe Affordable Canadian Medicines Act of 2 Lobbied to prevent the passage of provisions that would permit the importati defective counterfeit foreign products or foreign price controls.
16	Lobbying Issues	H.R.865 , Smallpox Vaccine Compensation and Safety Act of 2003, Lobbied t ensure a fair and reasonable vaccine compensation program.
16	Lobbying Issues	H.R.896 , Breast Cancer Prescription Drug Fairness Act of 2003, Lobbied to provide for greater access to affordable pharmaceutical products to treat can
16	Lobbying Issues	H.R.936 , Leave No Child Behind Act of 2003, Lobbied to ensure greater acc pediatric pharmaceutical products for children and for the development of b pediatric drugs.
16	Lobbying Issues	S.1009 , United States Emergency Plan for AIDS Relief Act of 2003, Lobbied increase government assistance to combat the Global AIDS crisis.
16	Lobbying Issues	S.1030 , HealthCARE Act of 2003, Lobbied to expand the number of individ and families with health insurance coverage and provide greater access to pharmaceutical products.
16	Lobbying Issues	S.11 , Patients First Act of 2003, Lobbied to ensure fair and appropriate acc pharmaceutical products.
16	Lobbying Issues	S.1101 , National Cancer Act of 2003, Lobbied for a comprehensive Federal relating to early detection of, treatment for, and the prevention of cancer.
16	Lobbying Issues	S.1159 , Hispanic Health Improvement Act of 2003, Lobbied to provide for programs and activities to improve the health of Hispanic individuals.
16	Lobbying Issues	S.1225, Greater Access to Affordable Pharmaceuticals Act, Lobbied to preve passage of specific provisions and amendments that are adverse to the indust
16	Lobbying Issues	S.1300 , Prescription Drug Consumer Information Act of 2003, Lobbied to prohibit a health plan from contracting with a pharmacy benenfit manager (unless the PBM satisfies certain requirements.
16	Lobbying Issues	S.1369 , A bill to ensure that prescription drug benefits offered to medicare e enrollees in the Federal Employees Health Benefits Program are at least equ the actuarial value of the prescription drug benefits offered to enrollees unde plan genera, Lobbied to prevent the passage of provisions and amendments t are adverse to the industry.
16	Lobbying Issues	S.1374, Better HEALTH Act of 2003, Lobbied to provide helath care profess with immediate relief from increased medical malpractice insurance costs an deal with the root causes of the medical malpractice insurance crisis.
16	Lobbying Issues	S.15 , Biodefense Improvement and Treatment for America Act, Lobbied to protect the industry's intellectual property and to provide patient access to affordable pharmaceutical products.
16	Lobbying Issues	S.1781, Pharmaceutical Market Access Act of 2003, Lobbied against passage
16	Lobbying Issues	S.1909, Stroke Treatment and Ongoing Prevention Act of 2003, Lobbied to support passage of patient access to affordable pharmaceutical products.
16	Lobbying Issues	S.2137, Pharmaceutical Market Access Act of 2003, Lobbied to prevent pass bill.

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	S.245 , Human Cloning Prohibition Act of 2003, Lobbied to prevent unnecess restrictions on legitimate scientific and clinical research.
16	Lobbying Issues	S.2507, Child Nutrition and WIC Reauthorization Act of 2004, Lobbied to en passage of WIC program.
16	Lobbying Issues	S.306 , Seniors Health and Independence Preservation Act of 2003, Lobbied t provide Medicare prescription drug benefit proposals that will provide great affordable access to drug products for America's seniors.
16	Lobbying Issues	S.448 , Leave No Child Behind Act of 2003, Lobbied to ensure greater acces pediatric pharmaceutical products for children and for the development of b pediatric drugs.
16	Lobbying Issues	S.465 , Access to Innovation for Medicare Patients Act of 2003, Lobbied to p the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.468 , Senior Nutrition Act of 2003, Lobbied to provide better access to nutritional products for seniors.
16	Lobbying Issues	S.477 , Preserving Prescription Drug Discounts Act, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.51 , Generic Pharmaceutical Access and Choice for Consumers Act of 2003 Lobbied to prevent the passage of provisions and amendments that are adver the industry.
16	Lobbying Issues	S.518 , Pancreatic Islet Cell Transplantation Act of 2003, Lobbied to prevent unnecessary restrictions on legitimate scientific and clinical research.
16	Lobbying Issues	S.542 , Rx Flexibility for States Act, Lobbied to ensure that states do not imp unreasonable drug rebate agreements in order to make outpatient prescriptic drugs accessible and affordable for residents of the state who are not otherwi eligible for medical assistance under Medicaid.
16	Lobbying Issues	S.581 , Health Care That Works for All Americans Act of 2003, Lobbied to e that there is fair and balanced public debate about how to improve the health system for Americans.
16	Lobbying Issues	S.607 , HEALTH Act of 2003, Lobbied to reduce the excessive burden the lia system places on health care delivery systems.
16	Lobbying Issues	S.666 , Biological, Chemical, and Radiological Weapons Countermeasures Research Act, Lobbied to ensure the reasonable and efficient development of counter bioterrorism pharmaceutical products.
16	Lobbying Issues	S.7 , Prescription Drug Benefit and Cost Containment Act of 2003, Lobbied t provide a Medicare prescription drug benefit that will enable millions of Am seniors to receive coverage for these products.
16	Lobbying Issues	S.722 , Dietary Supplement Safety Act of 2003, Lobbied to ensure that health claims for dietary supplants are based on sound scientific data.
16	Lobbying Issues	S.732 , Health Care Safety Net Oversight Act of 2003, Lobbied to ensure that independent and nonpartisan commission created by this bill to assess the he care needs of the uninsured and to monitor the financial stability of the Natic health care safety net be balanced and fair.
16	Lobbying Issues	S.874 , Sickle Cell Treatment Act of 2003, Lobbied to obtain the best bill for patient.
16	Lobbying Issues	S.906 , Health Care Access for Small Businesses Act of 2003, Lobbied to pro greater access to affordable pharmaceutical products.
16	Lobbying Issues	S.946 , Drug Competition Act of 2003, Lobbied to prevent the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.948 , Drug Company Gift Disclosure Act, Lobbied to ensure that the bill's requirements that prescription drug manufacturers, packers, and distributor disclose certain gifts provided in connection with detailing, promotional, or o marketing activities be fair and less burdensome.
16	Lobbying Issues	S.951 , Older Americans Prescription Drug Tax Relief Act, Lobbied for prov that would provide seniors with greater access to affordable pharmaceutical products.

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **INS** (one per page)

16. Specific Lobbying issues
H.R.1228 , Patient and Physician Safety and Protection Act of 2003, Lobbied to prevent the passage of provi amendments that are adverse to the industry.
H.R.1733 , Senior Bill of Rights Act of 2003, Lobbied to prevent the passage of provisions and amendments adverse to the industry.
H.R.597 , Patient Protection Act, Lobbied to prevent the passage of provisions and amendments that are ad industry.
S.952 , Patient and Physician Safety and Protection Act of 2003, Lobbied to prevent the passage of provisio amendments that are adverse to the industry.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Keaney, David	
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **MMM** (one per page)

16. Specific Lobbying issues
H.R.1 , Medicare Prescription Drug and Modernization Act of 2003, Lobbied to ensure the future financial the federal Medicare program and consumer choice.
H.R.1045 , Medicare Outpatient Prescription Drug Coverage Act of 2003, Lobbied to prevent the passage of and amendments that are adverse to the industry.
H.R.1199 , Medicare Rx Drug Benefit and Discount Act of 2003, Lobbied to prevent the passage of provisior impose unreasonable price controls on US manufacturers.
H.R.1382 , EMTALA Regulatory Improvement Act of 2003, Lobbied to ensure the future financial viability Medicare program and consumer choice.
H.R.1400 , Prescription Drug Fairness for Seniors Act of 2003, Lobbied to provide a Medicare prescription that will enable millions of America's seniors to receive coverage of these products.
S.2328, Pharmaceutical Market Access and Drug Safety Act of 2004, Lobbied to ensure safety of presciprito

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
Department of Health & Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Keaney, David	
Ryan, John	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	H.R.2409 , Safety Net Hospital Pharmacy Access Act of 2003, Lobbied to ens the future financial viability of the federal Medicare program and consumer choice.
16	Lobbying Issues	H.R.2473 , Medicare Prescription Drug and Modernization Act of 2003, Lob to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.2498 , Medicare Extension of Drugs to Seniors (MEDS) Act of 2003, Lol to provide a Medicare prescription drug benefit that will enable millions of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.2578 , Medicare for the 21st Century Act, Lobbied to provide a Medicai prescription drug benefit that will enable millions of America's seniors to rec coverage of these products.
16	Lobbying Issues	H.R.26 , Medicare Payment Restoration and Benefits Improvement Act of 20 Lobbied to provide a Medicare prescription drug benefit that will enable mil of America's seniors to receive coverage of these products.
16	Lobbying Issues	H.R.2606 , To amend title XVIII of the Social Security Act to provide prescri drug coverage under the Medicare Program, to make improvements in Medi payment for rural providers, and for other purposes, Lobbied to provide a Medicare prescription drug benefit that will enable millions of America's sen to receive coverage of these products.
16	Lobbying Issues	H.R.2631 , To provide that the actuarial value of the prescription drug benef offered to Medicare eligible enrollees by a plan under the Federal employees health benefits program shall be at least equal to the actuarial value of the prescription drug benefits off, Lobbied to provide a Medicare prescription d benefit that will enable millions of America's seniors to receive coverage of th products.
16	Lobbying Issues	H.R.513 , Medicare Rx Drug Discount Act of 2003, Lobbied to provide a Me prescription drug benefit that will enable millions of America's seniors to rec coverage of these products.
16	Lobbying Issues	H.R.960 , Seniors Health and Independence Preservation Act of 2003, Lobbi provide a Medicare prescription drug benefit that will enable millions of Am seniors to receive coverage of these products.
16	Lobbying Issues	H.R.980 , Access to Innovation for Medicare Patients Act of 2003, Lobbied t provide a Medicare prescription drug benefit that will enable millions of Am seniors to receive coverage of these products.
16	Lobbying Issues	S.10 , Health Care Coverage Expansion and Quality Improvement Act of 20(Lobbied to provide a Medicare prescription drug benefit that will enable mil of America's seniors to receive coverage of these products.
16	Lobbying Issues	S.1195 , Safety Net Hospital Pharmacy Access Act of 2003, Lobbied to ensur future financial viability of the federal Medicare program and consumer cho
16	Lobbying Issues	S.1332 , Medicare Educational Regulatory Reform, and Contracting Improv Act of 2003, Lobbied for fair regulatory relief, appeals process reforms, contracting flexibility, and education improvements under the Medicare pro
16	Lobbying Issues	S.1950, Medicare Prescription Drug Savings Act of 2003, Lobbied to prevent passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.2307, Reliable Entry for Medicines at Everyday Discounts through Import with Effective Safeguards Act of 2004, Lobbied to ensure safety of prescripti drugs.
16	Lobbying Issues	S.2493, Safe IMPORT Act of 2004 Safe Importation of Medical Products and Other Rx Therapies Act of 2004, Lobbied to ensure safety of prescription drugs.
16	Lobbying Issues	S.778 , Medicare Rx Drug Discount and Security Act of 2003, Lobbied to pr the passage of provisions and amendments that are adverse to the industry.
16	Lobbying Issues	S.891 , Prescription Drug Equity for Seniors Act of 2003, Lobbied to provid Medicare prescription drug benefit that will enable millions of America's sei to receive coverage of these products.

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	**Lobbying Issues**	**S.892 , Prescription Drug Fairness for Seniors Act of 2003, Lobbied to provi Medicare prescription drug benefit that will enable millions of America's sen to receive coverage of these products.**
16	**Lobbying Issues**	**Lobbied for changes in Medicare regulations regarding payment for prescrip drugs and against functional equivalence.**

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **TAX** (one per page)

16. Specific Lobbying issues
H.R.2896, American Jobs Creation Act of 2003, Lobbied for ensure passage of bill.
H.R.4520, American Jobs Creation Act of 2004, Lobbied for ensure passage of bill.
S.1637, Jumpstart Our Business Strength (JOBS) Act, Lobbied for ensure passage of bill.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Ryan, John	
Thompson, Richard	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **TOR** (one per page)

16. Specific Lobbying issues
S.2062, Class Action Fairness Act of 2004, Lobbied to ensure passage of legislation to reduce abuses in the le

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **TRD** (one per page)

16. Specific Lobbying issues
H.R. 4759, United States Australia Free Trade Agreement Implementation Act, Lobbied to support passage
S.1234 , Federal Trade Commission Reauthorization Act of 2003, Lobbied to prevent the passage of provisio amendments that are adverse to the industry.
S.2610, United States Australia Free Trade Agreement Implementation Act., Lobbied to support passage of Discussed European reclassification of ostomy products.
U.S. Chile FTA
Free Trade Agreeement of the Americas (FTAA)
Central America Free Trade Agreement (CAFTA)

17. House(s) of Congress and Federal agencies contacted ☐ Check if None
Department of Commerce
Department of Health & Human Services
House of Representatives
Office of U.S. Trade Representative
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Johnson, Mary-Sumpter	
Keaney, David	
Ryan, John	
Thompson, Richard	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City State/Zip (or Country)

22. New general description of client's business or activities

Pharmaceutical Research & Development

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

Keaney, David

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

ECN, ENV, LAW, LBR, MED, PHA, TEC

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Bu (city and state or cou

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registra or affiliated organization

8/12/2004

Signature _____ Date 8/12/2004

Printed Name and Title **Richard Thompson - Senior Vice President, Policy & Government Affairs** Pa